Neoplasm Recurrence, Local
"Neoplasm Recurrence, Local" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
| Descriptor ID |
D009364
|
| MeSH Number(s) |
C04.697.655 C23.550.727.655
|
| Concept/Terms |
Neoplasm Recurrence, Local- Neoplasm Recurrence, Local
- Local Neoplasm Recurrences
- Locoregional Neoplasm Recurrence
- Recurrences, Local Neoplasm
- Neoplasm Recurrences, Local
- Recurrence, Local Neoplasm
- Recurrence, Locoregional Neoplasm
- Local Neoplasm Recurrence
- Neoplasm Recurrence, Locoregional
- Locoregional Neoplasm Recurrences
- Neoplasm Recurrences, Locoregional
- Recurrences, Locoregional Neoplasm
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Recurrence, Local".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Recurrence, Local".
This graph shows the total number of publications written about "Neoplasm Recurrence, Local" by people in this website by year, and whether "Neoplasm Recurrence, Local" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 4 | 6 |
| 1997 | 0 | 6 | 6 |
| 1998 | 1 | 6 | 7 |
| 1999 | 1 | 0 | 1 |
| 2000 | 5 | 7 | 12 |
| 2001 | 1 | 14 | 15 |
| 2002 | 4 | 4 | 8 |
| 2003 | 4 | 8 | 12 |
| 2004 | 4 | 11 | 15 |
| 2005 | 6 | 10 | 16 |
| 2006 | 9 | 12 | 21 |
| 2007 | 12 | 7 | 19 |
| 2008 | 12 | 5 | 17 |
| 2009 | 9 | 15 | 24 |
| 2010 | 17 | 24 | 41 |
| 2011 | 9 | 18 | 27 |
| 2012 | 11 | 5 | 16 |
| 2013 | 19 | 16 | 35 |
| 2014 | 22 | 13 | 35 |
| 2015 | 21 | 17 | 38 |
| 2016 | 18 | 13 | 31 |
| 2017 | 24 | 19 | 43 |
| 2018 | 21 | 25 | 46 |
| 2019 | 20 | 22 | 42 |
| 2020 | 24 | 27 | 51 |
| 2021 | 12 | 42 | 54 |
| 2022 | 6 | 50 | 56 |
| 2023 | 2 | 45 | 47 |
| 2024 | 22 | 25 | 47 |
| 2025 | 35 | 13 | 48 |
| 2026 | 19 | 5 | 24 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm Recurrence, Local" by people in Profiles.
-
Marrow-ablative chemotherapy and re-irradiation are associated with improved overall survival in patients with relapsed central nervous system nongerminomatous germ cell tumors. J Neurooncol. 2026 Apr 17; 177(3).
-
Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors. Pediatr Blood Cancer. 2026 May; 73(5):e70199.
-
Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195.
-
Carbonic Anhydrase Inhibition Sensitizes Group 3 Medulloblastoma to Radiotherapy. Cancer Res. 2025 10 01; 85(19):3737-3751.
-
A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors. Cancer Res Commun. 2025 09 01; 5(9):1574-1583.
-
Molecular and clinical determinants of response to checkpoint inhibitor immunotherapy in glioblastoma. J Neurooncol. 2025 Oct; 175(1):453-461.
-
Relapse patterns among children and adolescents with Kaposi sarcoma in Malawi. Pediatr Hematol Oncol. 2025 Aug; 42(5):276-286.
-
Insurer and patient costs for repeat breast surgery after initial lumpectomy for breast cancer. Breast Cancer Res Treat. 2025 Aug; 212(3):457-465.
-
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
-
Consensus recommendations for systemic therapies in the management of relapsed Ewing sarcoma: A report from the National Ewing Sarcoma Tumor Board. Cancer. 2024 Dec 01; 130(23):4028-4039.